Curated News
By: NewsRamp Editorial Staff
May 01, 2025
TransCode Therapeutics Reports Positive Results in Phase 1a Trial of TTX-MC138 for Metastatic Cancer
TLDR
- Advantage: TransCode Therapeutics progresses in Phase 1a trial of TTX-MC138 for metastatic cancer treatment, showing promising results.
- How it works: TTX-MC138, an RNA-based therapeutic targeting microRNA-10b, demonstrated target engagement and dose-response relationship in early PK/PD data.
- Better tomorrow: TransCode's innovative RNA therapeutics aim to defeat cancer by treating metastatic tumors, offering hope for improved cancer treatments.
- Interesting: TTX-MC138's Phase 1a trial results show no significant toxicities, with patients demonstrating stable disease after seven months, supporting further evaluation in Phase 1b.
Impact - Why it Matters
This news matters as it highlights progress in developing a new treatment for metastatic cancer, potentially offering hope to patients. The positive results in the trial indicate a promising future for RNA-based therapeutics in targeting specific biomarkers. The advancement to Phase 1b signifies a step closer to providing more effective and safer treatment options for individuals battling metastatic disease.
Summary
TransCode Therapeutics (NASDAQ: RNAZ) announced positive results in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients received doses with no significant toxicities, and early data show target engagement and a dose-response relationship. The company plans to move to Phase 1b for further evaluation.
TransCode Therapeutics is focused on treating metastatic disease through RNA therapeutics. Its lead candidate, TTX-MC138, targets microRNA-10b, a biomarker of metastasis. The company aims to unlock therapeutic access to genetic targets for cancer treatment. BioMedWire, a communications platform, provides updates on biotech and life sciences sectors.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, TransCode Therapeutics Reports Positive Results in Phase 1a Trial of TTX-MC138 for Metastatic Cancer
